Trialect

Verified

NOIP: Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development

National Institutes of Health

Note: This is a Forecasted Opportunity.

The NIH Blueprint for Neuroscience Research is interested in continuing to support the BluePrint Neurotherapeutics Network for Small Molecules (BPN-SM)- a program designed to help investigators advance promising small-molecule therapeutics toward clinical testing. The BPN-SM program supports drug discovery and development activities in investigators’ own laboratories while also providing access to NIH-supported subject matter experts and contract research organizations (CROs) with capabilities in medicinal chemistry, pharmacokinetics, toxicology, formulation development, GMP synthesis, and Phase I clinical testing. By integrating NIH resources with industry-standard expertise, BPN-SM advances investigator-initiated drug discovery while enabling investigators to retain and strengthen their intellectual property while gaining hands-on experience in translational drug development.

The overarching goal of the program is to reduce the risk of scientific and therapy development sufficiently to enable external partners to take on late-stage development and ultimately bring new therapies to patients. In addition, this BPN program is specifically focused on small molecules and excludes biologics, because development, regulatory, and manufacturing considerations for each class of therapeutics differ substantially from each other. It will use a phased cooperative agreement mechanism which will enable the program to support innovative but higher-risk projects, with decisions of continued support being contingent on demonstrated feasibility of yearly milestones. A cooperative agreement framework is proposed because several key aspects of the program will involve collaborative activities between the investigators and NIH program staff, with substantial involvement beyond the normal scope of grant stewardship. The project principal investigator(s) and NIH program staff will work jointly with NIH-supported subject matter experts to coordinate and participate in all scientific and technical management aspects of the project.

Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop competitive projects and establish the cross-disciplinary collaborations necessary for success.

Estimated Post Date:

Nov 15, 2026

Estimated Application Due Date:

Jun 16, 2027

Specialties

Interdisciplinary

Medical - Basic Science

Medical - Translational

Medical

Medical - Clinical Science

Eligibility Requirements

Sponsor Details

Sponsor Institute/Organizations: National Institutes of Health

Sponsor Type: Government/Federal

Address: National Institutes of Health; 31 Center Drive; MSC 2220; Bethesda; MD 20892-2220; USA

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity